JW Pharmaceutical Future Growth

Future criteria checks 2/6

JW Pharmaceutical wird ein jährliches Wachstum der Erträge und Einnahmen um 29.1% bzw. 8.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich grow um 29.9% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.1% betragen.

Key information

29.1%

Earnings growth rate

48.2%

EPS growth rate

Pharmaceuticals earnings growth	43.9%
Revenue growth rate	8.6%
Future return on equity	18.1%
Analyst coverage	Low
Last updated	15 Feb 2024

Recent future growth updates

Recent updates

JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.

Jan 19

Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend

Dec 24

Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?

Nov 30

Earnings and Revenue Growth Forecasts

KOSE:A001060 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	889,967	72,500	33,400	88,950	3
12/31/2024	827,467	73,500	35,250	95,600	3
12/31/2023	748,527	37,006	46,452	87,157	N/A
9/30/2023	736,668	24,614	42,709	76,046	N/A
6/30/2023	722,312	50,572	29,078	58,339	N/A
3/31/2023	701,393	37,309	28,177	51,238	N/A
12/31/2022	684,351	31,892	44,412	56,764	N/A
9/30/2022	660,661	12,130	32,649	46,346	N/A
6/30/2022	639,806	8,930	37,194	50,657	N/A
3/31/2022	620,832	4,584	27,866	41,446	N/A
12/31/2021	606,585	-968	5,222	18,124	N/A
9/30/2021	581,827	-1,190	4,847	19,302	N/A
6/30/2021	569,978	-3,329	22,689	36,349	N/A
3/31/2021	560,407	-8,469	28,086	43,146	N/A
12/31/2020	547,336	-15,241	48,015	63,054	N/A
9/30/2020	516,529	-31,512	65,219	77,881	N/A
6/30/2020	512,402	-33,320	36,132	49,800	N/A
3/31/2020	510,079	-23,341	43,389	56,719	N/A
12/31/2019	511,335	-25,275	42,354	55,531	N/A
9/30/2019	524,767	-9,432	3,533	16,086	N/A
6/30/2019	538,269	-8,270	40,264	51,987	N/A
3/31/2019	536,808	-659	61,987	72,856	N/A
12/31/2018	537,182	8,057	42,829	52,110	N/A
9/30/2018	534,919	9,113	56,378	66,480	N/A
6/30/2018	521,666	12,567	27,538	35,484	N/A
3/31/2018	510,284	2,417	-3,936	5,770	N/A
12/31/2017	502,919	-742	23,470	33,450	N/A
9/30/2017	490,656	14,223	N/A	36,480	N/A
6/30/2017	476,290	3,697	N/A	6,678	N/A
3/31/2017	471,517	-11,472	N/A	14,991	N/A
12/31/2016	467,465	-10,934	N/A	6,739	N/A
9/30/2016	460,523	-18,836	N/A	-799	N/A
6/30/2016	452,150	-12,991	N/A	17,745	N/A
3/31/2016	447,417	2,860	N/A	28,884	N/A
12/31/2015	434,352	1,921	N/A	-4,175	N/A
9/30/2015	447,788	1,575	N/A	8,860	N/A
6/30/2015	439,802	1,064	N/A	15,286	N/A
3/31/2015	426,011	-3,378	N/A	-12,885	N/A
12/31/2014	412,791	-2,357	N/A	7,279	N/A
9/30/2014	386,064	-2,651	N/A	6,994	N/A
6/30/2014	386,067	-2,648	N/A	-16,031	N/A
3/31/2014	395,535	3,095	N/A	16,653	N/A
12/31/2013	394,182	2,275	N/A	18,725	N/A
9/30/2013	401,971	-6,575	N/A	2,775	N/A
6/30/2013	397,590	-9,125	N/A	9,541	N/A

Analyst Future Growth Forecasts

Einkommen vs. Sparrate: A001060Das prognostizierte Gewinnwachstum (29.1% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: A001060Die Erträge des Unternehmens (29.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt KR (31.1% pro Jahr).

Hohe Wachstumserträge: A001060Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: A001060Die Einnahmen des Unternehmens (8.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt KR (9.3% pro Jahr).

Hohe Wachstumseinnahmen: A001060Die Einnahmen des Unternehmens (8.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Earnings per Share Growth Forecasts

Future Return on Equity

Künftige Eigenkapitalrendite: A001060Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.9%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

JW Pharmaceutical Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 22% to ₩40,163

Price target increased by 7.7% to ₩36,245

Price target decreased to ₩33,000

Price target increased to ₩40,000

Recent updates

Now 21% overvalued

JW Pharmaceutical's (KRX:001060) Earnings Are Of Questionable Quality

Full year 2023 earnings: EPS misses analyst expectations

Now 21% overvalued after recent price rise

Price target increased by 22% to ₩40,163

Investor sentiment improves as stock rises 17%

New minor risk - Earnings quality

Investor sentiment improves as stock rises 21%

New minor risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued

Investor sentiment improves as stock rises 19%

Price target increased by 7.7% to ₩36,245

New minor risk - Share price stability

Investor sentiment improves as stock rises 24%

Full year 2022 earnings released: EPS: ₩1,331 (vs ₩41.00 loss in FY 2021)

Upcoming dividend of ₩375 per share

No independent directors

Price target decreased to ₩33,000

Price target increased to ₩40,000

No independent directors

Upcoming dividend of ₩316 per share

Is JW Pharmaceutical Corporation (KRX:001060) An Attractive Dividend Stock?

Full year 2020 earnings released: ₩676 loss per share (vs ₩1,158 loss in FY 2019)

How Many JW Pharmaceutical Corporation (KRX:001060) Shares Do Institutions Own?

Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?

JW Pharmaceutical Corporation, Annual General Meeting, Mar 26, 2021

New 90-day low: ₩30,550

JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.

New 90-day high: ₩36,200

Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend

New 90-day high: ₩36,500

Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?

Third quarter 2020 earnings released: EPS ₩134

New 90-day low: ₩31,950

New 90-day high: ₩40,800

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies